Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Texting too tempting for college students even when inappropriate

  • Mighty microexons take center stage in shaping of the brain

  • New imaging tool targets degenerative diseases

  • Publication bias and 'spin' raise questions about drugs for anxiety disorders

  • World first study reveals antibodies that may trigger psychosis in children

  • Poses of power are less powerful than we thought

  • Well-designed classrooms can boost learning progress in primary school pupils by up to 16% in a single year, research reveals

  • Interview blues: Anxious, slow talkers often do not get the job

  • Depression often co-occurs with joint diseases

  • Negotiating: Careful Choice of Words Increases Chances of Success

  •